Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 5, 2004, Pages 347-354

  Chalandon, Yves ^a   Roosnek, Eddy ^a   Mermillod, Bernadette ^a   Newton, Anita ^a   Ozsahin, Hulya ^a   Wacker, Pierre ^a   Helg, Claudine ^a   Chapuis, Bernard ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Allogeneic stem cell transplantation; Defibrotide; Prophylaxis; Veno occlusive disease

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; BILIRUBIN; BUSULFAN; CAMPATH 1 H; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFIBROTIDE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ABDOMINAL CRAMP; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE SEVERITY; FEMALE; FEVER; GRAFT SURVIVAL; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BILIRUBIN; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPARIN; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; POLYDEOXYRIBONUCLEOTIDES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 1942456498     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.01.002     Document Type: Article

References (41)

1. Bearman S.I. The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 85 1995 3005-3020
2. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation Eur J Haematol 64 2000 281-291
3. Carreras E. Bertz H. Arcese W. et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party Blood 92 1998 3599-3604
4. Bearman S.I. Anderson G.L. Mori M. Hinds M.S. Shulman H.M. McDonald G.B. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation J Clin Oncol 11 1993 1729-1736
5. McDonald G.B. Sharma P. Matthews D.E. Shulman H.M. Thomas E.D. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors Hepatology 4 1984 116-122
6. Shulman H.M. Gown A.M. Nugent D.J. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules Am J Pathol 127 1987 549-558
7. Rollins B.J. Hepatic veno-occlusive disease Am J Med 81 1986 297-306
8. Shulman H.M. Fisher L.B. Schoch H.G. Henne K.W. McDonald G.B. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms Hepatology 19 1994 1171-1181
9. DeLeve L.D. McCuskey R.S. Wang X. et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease Hepatology 29 1999 1779-1791
10. DeLeve L.D. Shulman H.M. McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease) Semin Liver Dis 22 2002 27-42
11. Salat C. Holler E. Kolb H.J. et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation Blood 89 1997 2184-2188
12. Scrobohaci M.L. Drouet L. Monem-Mansi A. et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers Thromb Res 63 1991 509-519
13. Attal M. Huguet F. Rubie H. et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial Blood 79 1992 2834-2840
14. Or R. Nagler A. Shpilberg O. et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients Transplantation 61 1996 1067-1071
15. Gluckman E. Jolivet I. Scrobohaci M.L. et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation Br J Haematol 74 1990 277-281
16. Essell J.H. Schroeder M.T. Harman G.S. et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial Ann Intern Med 128 1998 975-981
17. Ruutu T. Eriksson B. Remes K. et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation Blood 100 2002 1977-1983
18. Attal M. Huguet F. Rubie H. et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial Blood 82 1993 732-736
19. Chopra R. Eaton J.D. Grassi A. et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study Br J Haematol 111 2000 1122-1129
20. Richardson P.G. Elias A.D. Krishnan A. et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population Blood 92 1998 737-744
21. Richardson P.G. Murakami C. Jin Z. et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome Blood 100 2002 4337-4343
22. Coppell J.A. Brown S.A. Perry D.J. Veno-occlusive disease: cytokines, genetics, and haemostasis Blood Rev 17 2003 63-70
23. Carreras E. Granena A. Rozman C. Hepatic veno-occlusive disease after bone marrow transplant Blood Rev 7 1993 43-51
24. Jones R.J. Lee K.S. Beschorner W.E. et al. Venoocclusive disease of the liver following bone marrow transplantation Transplantation 44 1987 778-783
25. Bieri S. Helg C. Chapuis B. Miralbell R. Total body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys 49 2001 1071-1077
26. Storb R. Pepe M. Anasetti C. et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 76 1990 1037-1045
27. Storb R. Deeg H.J. Whitehead J. et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia N Engl J Med 314 1986 729-735
28. Kottaridis P.D. Milligan D.W. Chopra R. et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419-2425
29. Glucksberg H. Storb R. Fefer A. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 18 1974 295-304
30. Einsele H. Ehninger G. Hebart H. et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation Blood 86 1995 2815-2820
31. Kaplan E.L. Meier O. Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457-481
32. Hagglund H. Remberger M. Klaesson S. Lonnqvist B. Ljungman P. Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation Blood 92 1998 4568-4572
33. McDonald G.B. Hinds M.S. Fisher L.D. et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 118 1993 255-267
34. Bearman S.I. Lee J.L. Baron A.E. McDonald G.B. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients Blood 89 1997 1501-1506
35. Goldberg S.L. Ellent D. Shtrambrand D. et al. Gemtuzumab ozogamicin (Mylotarg) prior to allogeneic hematopoietic stem cell transplantation increases the risk of hepatic veno-occlusive disease Blood 100 2002 415a
36. Park S.H. Lee M.H. Lee H. et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation Bone Marrow Transplant 29 2002 137-143
37. Reiss U. Cowan M. McMillan A. Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients J Pediatr Hematol Oncol 24 2002 746-750
38. Shulman H.M. Luk K. Deeg H.J. Shuman W.B. Storb R. Induction of hepatic veno-occlusive disease in dogs Am J Pathol 126 1987 114-125
39. Lebrec D. Benhamou J.P. Noncirrhotic intrahepatic portal hypertension Semin Liver Dis 6 1986 332-340
40. Falanga A. Vignoli A. Marchetti M. Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells Leukemia 17 2003 1636-1642
41. Eissner G. Multhoff G. Gerbitz A. et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide Blood 100 2002 334-340